Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)

Organon

Status and phase: Completed; Phase 3

Conditions: Contraception

Treatments: Drug: LNG-EE; Drug: NOMAC-E2

Study type: Interventional

Funder types: Industry

Identifiers

NCT00511342

Organon Protocol No. 292005

P05765

Details and patient eligibility

About

The primary purpose of this study is to evaluate the effects of the NOMAC-E2 combined oral contraceptive (COC) on bone mineral density (BMD).

Enrollment: 110 patients

Sex: Female

Ages: 20 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Sexually active women, at risk for pregnancy and not planning to use condoms

during treatment;

• At least 20 but not older than 35 years of age at the time of screening;
• BMI = 17 and = 35;
• Good physical and mental health;
• Willing to give informed consent in writing;
• Willing to take part in the trial for two years.

Exclusion criteria

• Family history of osteoporotic fracture below the age of 70;

• Postgastrectomy;

• History of eating disorder, viz. anorexia nervosa, bulimia;

• Endocrine disorder (including controlled diabetes, [para]thyroid disease, Cushing's disease);

• Rheumatoid arthritis;

• Significant scoliosis;

• Fasting parathyroid hormone (PTH) outside the reference range at screening;

• Fasting calcitonin outside the reference range at screening;

• Prolactin above the reference range (hyperprolactinemia) at screening;

• Fasting cholesterol and/or triglycerides above the reference range for age at screening (treatment with lipid lowering drugs not allowed);

• Engaging in vigorous exercise such as marathon, competitive swimming, triathlon;

• Smoking more than ten cigarettes/day;

• Use of more than two units of alcohol a day;

• Use of one or more of the following drugs:

  • gonadotropin releasing hormone (GnRH) analogues (also past use for more than six months at any time, or for any period of time less than six months ago is a contraindication);
  • systemic or inhaled administration of corticosteroids (also past use for more than one year, less than five years ago or any period of time in the past year is a contraindication);
  • thiazide diuretics;
  • thyroid hormone;
  • bisphosphonates;
  • calcium supplementation in combination with vitamin D supplementation/

calcitonin;

• ever treatment after childhood with fluorides;

  • Contraindications for contraceptive steroids
  • An abnormal cervical smear (i.e.: dysplasia, cervical intraepithelial neoplasia[CIN], squamous intraepithelial lesion [SIL], carcinoma in situ, invasive carcinoma) at screening;
  • Clinically relevant abnormal laboratory result at screening as judged by the investigator;
  • Use of an injectable hormonal method of contraception; within 6 months of an injection with a 3-month duration, within 4 months of an injection with a 2-month duration, within 2 months of an injection with a 1-month duration;
  • Within 12 months after a pregnancy prior to the start of trial medication;
  • Breastfeeding or within 12 months after stopping breastfeeding prior to the start of trial medication;
  • Present use or use within 2 months prior to the start of the trial medication of the following drugs: phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, felbamate, rifampicin, nelfinavir, ritonavir, griseofulvin, ketoconazole, sex steroids (other than pre- and post-treatment contraceptive method) and herbal remedies containing Hypericum perforatum (St John's Wort);
  • Administration of investigational drugs and/or participation in another clinical trial within 2 months prior to the start of the trial medication or during the trial period.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

110 participants in 2 patient groups

NOMAC-E2

Experimental group

Description:

Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic COC

Treatment:

Drug: NOMAC-E2

LNG-EE

Active Comparator group

Description:

Levonorgestrel (LNG) and Ethinyl Estradiol (EE), 0.150 mg LNG and 0.030 mg EE monophasic COC

Treatment:

Drug: LNG-EE